51 completed, 7 unknown, 1 active not recruiting, 1 withdrawn. 55 Phase 1, 4 Not applicable, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 55 | Completed 46, Unknown 7, Active not recruiting 1, Withdrawn 1 |
| Not applicable | 4 | Completed 4 |
| Phase 2 | 2 | Completed 2 |
Follow Healthy Male Subjects: new trials by email Literature Review of Healthy Male Subjects trials Research Report on Healthy Male Subjects
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare the Auto-injector and Pre-filled Syringe of CT-P52 in Healthy Male Subjects CT-P52 - Healthy Male Subjects | Phase 1 | Completed | Celltrion | 218 | 2026-01-26 | 2026-07-17 |
| A Study to Evaluate the PK Similarity of AK112 in Healthy Chinese Male Subjects AK112 (New Site), AK112 (Original Site) - Healthy Male Subjects | Phase 1 | Active not recruiting | Akeso | 108 | 2025-12-11 | 2026-03-09 |
| A Study to Compare the Auto-injector and Pre-filled Syringe of CT-P43 in Healthy Male Subjects CT-P43 - Healthy Male Subjects | Phase 1 | Completed | Celltrion | 162 | 2025-05-30 | 2026-02-24 |
| A Drug-drug Interaction Study With TS-172 in Healthy Adult Male Subjects Triazolam and TS-172, TS-172 and itraconazole - Healthy Male Subjects | Phase 1 | Completed | Taisho Pharmaceutical Co., Ltd. | 30 | 2025-03-11 | 2025-05-15 |
| A Mass Balance Study of TS-172 in Healthy Adult Subjects [14C] TS-172 - Healthy Male Subjects | Phase 1 | Completed | Taisho Pharmaceutical Co., Ltd. | 6 | 2024-09-26 | 2025-02-28 |
| A Study of PET/CT Imaging Using INR101 Injection in Healthy Male Subjects and Patients With Suspected Prostate Cancer INR101 - Healthy Male Subjects, Suspected Prostate Cancer | Phase 1 / Phase 2 | Completed | Yunhe Pharmaceutical (Tianjin) Co., Ltd | 32 | 2024-05-23 | 2024-10-30 |
| To Compare the Pharmacokinetics, Safety and Immunogenicity of CT-P55 and Cosentyx in Healthy Subjects CT-P55, US-licensed Cosentyx, EU-approved Cosentyx - Healthy Male Subjects | Phase 1 | Completed | Celltrion | 172 | 2024-01-12 | 2025-07-08 |
| Compare the Pharmacokinetics and Safety of BAT3306 Injection Versus KEYTRUDA® Administered in Healthy Male Subjects Recombinant Humanized Anti-PD-1 Monoclonal Antibody Solution for Injection, Pembrolizumab injection - Healthy Male Subjects | Phase 1 | Completed | Bio-Thera Solutions | 59 | 2023-11-05 | 2024-10-30 |
| ADME Study of [14C] Yiqibuvir in Healthy Male Subjects [14C] Yiqibuvir - Healthy Male Subjects | Phase 1 | Completed | Sunshine Lake Pharma Co., Ltd. | 8 | 2023-08-07 | 2024-02-21 |
| Study of RPT193 in Healthy Adult Male Subjects 14C RPT193 - Healthy Male Subjects | Phase 1 | Completed | RAPT Therapeutics, Inc., a member of the GSK plc group of companies | 7 | 2023-07-05 | 2023-11-29 |
| A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects Savolitinib, Fluvoxamine - Healthy Male Subjects | Phase 1 | Completed | AstraZeneca | 16 | 2023-06-02 | 2023-08-29 |
| A Study to Assess the Effects of Savolitinib on the Pharmacokinetics of Digoxin, Rosuvastatin, Metformin, and Furosemide in Healthy Male Subjects Savolitinib, Digoxin, Metformin Hydrochloride - Healthy Male Subjects | Phase 1 | Completed | AstraZeneca | 6 | 2023-04-25 | 2023-07-13 |
| Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male Volunteers tafolecimab (a modified manufacturing process), tafolecimab (a original manufacturing process) - Healthy Male Subjects | Phase 1 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 166 | 2023-03-06 | 2023-09-13 |
| ADME Study of [14C] Antaitavir Hasophate in Healthy Male Subjects [14C] Antaitavir Hasophate - Healthy Male Subjects | Phase 1 | Completed | Sunshine Lake Pharma Co., Ltd. | 6 | 2022-11-15 | 2023-01-05 |
| A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Subjects AK104 (before the change), AK104 (after the change) - Healthy Male Subjects | Phase 1 | Completed | Akeso | 100 | 2022-10-25 | 2024-05-16 |
| A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects TAS-303, [14C]TAS-303 - Healthy Male Subjects | Phase 1 | Completed | Taiho Pharmaceutical Co., Ltd. | 6 | 2022-09-07 | 2023-08-07 |
| A Clinical Trial of XZP-3287 for Material Balance [14C]XZP-3287 - Healthy Male Subjects | Phase 1 | Unknown | Xuanzhu Biopharmaceutical Co., Ltd. | 10 | 2022-08-02 | 2022-07-28 |
| AVT03 With Prolia in Healthy Male Subjects AVT03, Prolia - Healthy Male Subjects | Phase 1 | Completed | Alvotech Swiss AG | 209 | 2022-06-29 | 2024-05-29 |
| A Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of the Fixed-Dose Combination of Pertuzumab and Trastuzumab Administered Subcutaneously Using a Handheld Syringe or Using the On-Body Delivery System Fixed-Dose Combination of Pertuzumab and Trastuzumab SC (PH FDC SC), Handheld Syringe with Hypodermic Needle, On-Body Delivery System - Healthy Male Subjects | Phase 1 | Completed | Hoffmann-La Roche | 151 | 2022-05-30 | 2024-09-23 |
| Phase I Study of Sintilimab in Healthy Chinese Male Subjects sintilimab (after the change), sintilimab (before the change) - Healthy Male Subjects | Phase 1 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 117 | 2022-04-13 | 2023-08-21 |
Showing 20 of 60. Sign in to see all of them.
Cardiovascular Diseases (1) · Hypertension (1) · Motor Activity (1)
Behavior (1) · Cardiovascular Diseases (1) · Vascular Diseases (1)
Amlodipine, Valsartan Drug Combination (4) · Amlodipine (3) · Valsartan (3) · 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine (2) · Atorvastatin (2) · Bevacizumab (2) · Furosemide (2) · Rosuvastatin Calcium (2) · levamlodipine (2) · AZD9977 (1) · Breakfast (1) · Capsules (1) · Denosumab (1) · Digoxin (1) · Filgrastim (1)
Ahn-Gook Pharmaceuticals Co.,Ltd (4) · AstraZeneca (4) · Celltrion (4) · Hanlim Pharm. Co., Ltd. (4) · Innovent Biologics (Suzhou) Co. Ltd. (3) · Jiangsu HengRui Medicine Co., Ltd. (3) · Taisho Pharmaceutical Co., Ltd. (3) · Akeso (2) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (2) · Sunshine Lake Pharma Co., Ltd. (2) · Taiho Pharmaceutical Co., Ltd. (2) · ARCIM Institute Academic Research in Complementary and Integrative Medicine (1) · Alvotech Swiss AG (1) · Astellas Pharma Europe B.V. (1) · Bio-Thera Solutions (1)
China (18) · South Korea (9) · Japan (7) · United States (5) · United Kingdom (4) · Australia (3) · Germany (3) · Netherlands (3) · Bulgaria (2) · New Zealand (2) · Belgium (1) · Denmark (1) · Poland (1) · South Africa (1) · Switzerland (1)
KyoungSook Kim, PhD (2) · Annelize Koch, MBChB, FFPM (1) · Antonio Rusca, MD (1) · Chen Yu, M.D. (1) · Chul Woo Kim (1) · Dr. Nadine Abdullah (1) · Edith Feskens, PHd (1) · Felicitas Bullo (1) · Fugeng Liu, BD (1) · Gangyi Liu (1) · Hyewon Chung (1) · Jae Gook Shin, MD (1)
PMID 24555723, PMID 34086067, PMID 37183779, PMID 39111823, PMID 39840517, PMID 40357744, PMID 40514611, PMID 41665131
2015 (1), 2018 (1), R01MH058681 (1)